Human Molecular Genetics Advance Access originally published online on December 2, 2008
Human Molecular Genetics 2009 18(5):809-823; doi:10.1093/hmg/ddn407
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Combined kinase inhibition modulates parkin inactivation
1 Institute of Parasitology and Biomedicine ‘López-Neyra’, Consejo Superior de Investigaciones Científicas (CSIC), Granada, Spain 2 Department of Neurology, Virgen de las Nieves University Hospital, Granada, Spain 3 Institute of Neuropathology, IDIBELL-University Hospital Bellvitge, University of Barcelona, Llobregat, Spain
* To whom correspondence should be addressed. Tel: +34 958181654; Fax: +34 958181632; Email: sabine.hilfiker{at}ipb.csic.es
Received October 3, 2008; Accepted November 30, 2008
Mutations in the parkin gene cause autosomal-recessive, juvenile-onset parkinsonism, and parkin dysfunction may also play a role in the pathogenesis of sporadic Parkinson disease (PD). Although its precise function remains largely unknown, parkin seems to play a neuroprotective role. Several studies indicate that changes in parkin solubility induced by post-translational modifications, such as S-nitrosylation or dopamine modification, comprise one mechanism of parkin inactivation associated with disease. Protein phosphorylation events have recently been linked to the molecular mechanism(s) underlying PD, but the role of this post-translational modification for parkin function has remained unclear. Here we report that compound phosphorylation of parkin by both casein kinase I and cyclin-dependent kinase 5 (cdk5) decreases parkin solubility, leading to its aggregation and inactivation. Combined kinase inhibition partially reverses the aggregative properties of several pathogenic point mutants in cultured cells. Enhanced parkin phosphorylation is detected in distinct brain areas of individuals with sporadic PD and correlates with increases in the levels of p25, the activator of cdk5. These findings indicate that casein kinase I and cdk5 may represent novel combinatorial therapeutic targets for treating PD.